

Copper-Catalyzed Regioselective and Diastereoselective Synthesis of Borylated 1-Benzo[b]azepines

DingXi Li, Yeji Park, and Jaesook Yun*®

Department of Chemistry and Institute of Basic Science, Sungkyunkwan University, Suwon 440-746, Korea

Supporting Information

ABSTRACT: A practical regioselective and diastereoselective synthesis of functionalized 1-benzo[b]azepines by copper-catalyzed intramolecular cyclization has been developed. The reaction involves borylcupration of a mixture of (E/Z)-1,3-dienes, followed by capture of the generated (Z)-allylcopper species with an imine to produce 7-membered *N*-hetero-



cycles as single diastereomers. The reaction is applicable to various (E/Z)-dienyl arenes with an imine moiety at the *ortho*position, including aryl, alkyl, and heterocyclic aldimines, and ketimines, affording borylated 2,3-*cis*-substituted 1benzo[*b*]azepines in good yields.

B enzannulated nitrogen heterocycles are key structural elements, frequently appearing in biologically active molecules, synthetic drugs, and drug candidates.¹ In particular, compounds bearing a 7-membered ring skeleton have been incorporated into many commercial pharmaceuticals, such as a drug against Gram-positive and Gram-negative bacteria (ACHN-245),² an anti-HIV-1 agent (orally active CCRS antagonist),³ and a potential drug for the treatment of pathological diseases related to hydroelectrolyte imbalances (C9) (see Figure 1).⁴ As such, growing efforts have been



Figure 1. Bioactive compounds containing 1-benzo[*b*]azepine skeletons.

directed toward efficient preparation of the 1-benzo[b]azepine backbone. Newly developed methods, including catalytic RCM reactions,⁵ radical cyclization reactions,⁶ and catalytic [5 + 2] cycloadditions,⁷ have worked well in the preparation of valuable scaffolds, but the construction of two adjacent stereocenters on the 1-benzp[b]azepine ring with high stereoselectivity remains difficult. Other methods, such as Ircatalyzed allylic substitution via nucleophilic addition of amine,⁸ carbene C–H or C–C insertions,⁹ ring expansion by Beckmann rearrangement^{10a} and Schmidt reaction,^{10b} and others,¹¹ generally require specially functionalized substrates or expensive catalysts and give low stereoselectivity. Therefore, the development of reliable methods to construct the 1benzo[b]azepine backbones from readily available starting materials is a highly desirable, yet challenging objective.

Over the past decades, the copper-catalyzed allylation of imines has received much attention, as it is an efficient route to homoallylic amines.¹² Recently, Liao and co-workers have developed an asymmetric allylation of imines by coppercatalyzed borylative coupling of pure 1,3-dienes and aldimines in an intermolecular process (Scheme 1a).^{12g} More recently,

Scheme 1. Cu-Catalyzed Regioselective and Diastereoselective Borylative Coupling of Dienyl Arenes and Imines



our group and others have introduced copper-catalyzed asymmetric borylative intramolecular cyclization of vinyl arenes with tethered aldimines to produce *cis*-indolines, 5-membered *N*-heterocycles (Scheme 1b).^{13,14} Based on this success, we turned our attention to dienyl arenes (1) containing tethered imines. When we applied Cu–Bpin catalyst to 1, we found that a 7-membered ring unexpectedly formed, instead of the vinyl indolines (Scheme 1c). Herein, we report new developments in the copper-catalyzed borylative

Received: October 15, 2018

coupling, whereby an NHC–Cu–Bpin complex added to a mixture of (E/Z)-diene substrates combined with a tethered imine in an intramolecular process to afford 2,3-substituted 1-benzo[*b*]azepines with high efficiency and diastereoselectivity.

We used a mixture of (E/Z)-dienyl arenes 1a as our model substrate without isolation of each individual isomer in the presence of catalytic copper chloride, LiOt-Bu, B₂pin₂, and various ligands (Table 1). Complete regioselectivity and





^{*a*}Reactions were conducted on a 0.2 mmol scale. ^{*b*}Conversions and yields were determined by ¹H NMR analysis of the crude reaction mixture, using dimethylformamide (DMF) as an internal standard. Isolated yield of **2a** is shown in parentheses. ^{*c*}5 mol % of copper salt and ligand were used. ^{*d*}Not detected.

stereoselectivity were observed with the triphenylphosphine ligand (Table 1, entry 1). Unfortunately, the bisphosphine *rac*binap ligand gave low diastereoselectivity (Table 1, entry 2) compared to the flexible bisphosphine ligand, dppb (Table 1, entry 3). Gratifyingly, *N*-heterocyclic carbene copper(I) complexes, IMesCuCl and bulky IPrCuCl were highly active, giving full conversion and high yield of *cis*-2a¹⁵ with perfect diastereoselectivity (Table 1, entries 4 and 5), while SIMesCuCl resulted in an appreciably lower yield (Table 1, entry 6). In particular, a decrease in the amount of base from a stoichiometric quantity to a substoichiometric amount considerably decreased the conversion and yield (Table 1, entry 7), indicating a stoichiometric amount of base was necessary for the catalytic cycle.

With the optimized conditions in hand, we examined the substrate scope of this method using various dienyl arenes (see Scheme 2). First, substituent effects on the aryl ring (\mathbb{R}^2) of the imine moiety were investigated. Sterically bulky groups, such as *ortho*-methyl (**2b**) and naphthyl (**2c**), were compatible with this catalytic system and resulted in good to high yields, even on a gram scale. However, an electron-withdrawing substituent on the aromatic ring such as –CN at the *meta*-position (**2d**) and –Br at the *para*-position (**2e**) resulted in slightly decreased yields of the desired 1-benzo[*b*]azepines. The substrate with an electron-donating methoxy group at the *para*-position of the imine moiety gave the corresponding borylated 1-benzo[*b*].





"Reactions were conducted on a 0.2 mmol scale. Yields of isolated products are shown. ^bGram scale (2.9 mmol) reaction of 1c was performed to obtain 1.1 g of $2c_{\rm j}$ B₂pin₂ (1.65 equiv), IMesCuCl (2 mol %), and LiOt-Bu (1.6 equiv) were used. ^cPure (*E*)-isomer was used.

azepine (2f) in good yield. The reaction of imines containing 3-thiophene and 2-thiophene afforded the corresponding *cis*-1benzo[b] azepines (2g and 2h) in moderate to good yield. In addition, the unstable 1-benzo [b] azepines (2i and 2j) containing a vinyl and an alkyl substituent were oxidized to the isolable corresponding alcohols with NaBO₃·4H₂O (3i and 3i) in moderate yield. Next, different substituents (R^1) on the phenyl ring of the dienyl arene were examined. Substrates with an electron-donating substituent at the para-position, relative to the imine moiety, produced 2k in moderate yield. A methyl substituent at the para-position (11) or ortho-position (1m) to the dienyl group resulted in moderate yields as well. Unfortunately, substrates with either a strong electrondonating methoxy substituent or strong electron-withdrawing fluorine atom at the para-position to the dienyl group exhibited poor reactivity.¹⁶

In addition, less-reactive aryl ketimines were examined and were found to produce trisubstituted 1-benzo[b]azepines in good yields as single diastereoisomers under the optimized catalytic conditions (see Scheme 3). Methyl phenyl ketimine (4a), cyclic ketimine (4b), and ketimines containing an electron-withdrawing (4c) or electron-donating substituent (4d) resulted in moderate to good yields and excellent diastereoselectivity. The reaction of ketimines containing 3thiophene and 2-thiophene afforded the corresponding 1Scheme 3. Substrate Scope of the Copper-Catalyzed Borylative Cyclization^{*a*}



^aReactions were conducted on a 0.2 mmol scale. Yields of isolated products are shown.

benzo[*b*]azepines (**5e** and **5f**) in good yields. The relative configuration of **5a** was ascertained by X-ray crystallographic analysis and NOE analysis.

Finally, asymmetric reactions were briefly investigated using the Kündig-type NHC ligand, which previously has been reported to show high efficiency in copper-catalyzed intermolecular allylations of imines (see Scheme 4).^{12d} A 1:1

Scheme 4. Asymmetric Copper-Catalyzed Borylative Cyclization^a



^{*a*}Reactions were conducted on a 0.2 mmol scale. Yields of isolated products are shown. The *ee* values were determined by HPLC analysis.

mixture of (E/Z)-1a was converted to 2a in 85% yield and 20% ee¹⁷ (eq 1 in Scheme 4). With pure (*E*)-1a, a similar yield was obtained, but with an increased ee value (eq 2 in Scheme 4), which indicated that the asymmetric cyclization was affected by the E/Z ratio of dienyl arene, and the pure isomer could be used for better chiral induction.

The proposed catalytic cycle is shown in Scheme 5. The LCu–Bpin species (A) is generated from the reaction of IMes–CuCl, base, and B₂pin₂. This species then undergoes 1,4-borylcupration with the mixture of (E/Z)-1,3-dienes 1 to produce (Z)- σ -allylcopper intermediate B.¹⁸ The allylcopper B

Scheme 5. Proposed Catalytic Cycle



adds as a nucleophile to the imine intramolecularly to form a cyclized 1-benzo[b]azepine **D** through a 6-membered ring transition state **C** with its R_L substituent in the favored equatorial position. Finally, the catalytic cycle is completed by ligand exchange with LiOt-Bu and B₂pin₂. The complexation of copper to the imine in the allylcopper intermediate appears to be responsible for 7-membered ring formation via a chairlike transition state.^{12c,e,14}

In summary, we have developed a mild and general coppercatalyzed process for the facile construction of 2,3-substituted *cis*-1-benzo[*b*]azepines with excellent diastereoselectivity via NHC-Cu-catalyzed intramolecular borylative cyclization. This process tolerates a broad range of functionalized aryl, alkyl, heterocyclic aldimines, and various ketimines, providing rapid access to 2,3-substituted *cis*-1-benzo[*b*]azepines. In this diastereoselective protocol, a mixture of (*E*/*Z*)-dienyl arenes, instead of pure dienyl arene could be used to deliver high diastereoselectivity. Investigation of the asymmetric intramolecular cyclization is currently underway and will be reported in due course.

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.or-glett.8b03286.

Experimental procedures, characterization of products, and copies of ¹H and ¹³C NMR (PDF)

Accession Codes

CCDC 1863923 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge via www.ccdc.cam.ac.uk/data_request/cif, or by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12 Union Road, Cambridge CB2 1EZ, UK; fax: + 44 1223 336033

AUTHOR INFORMATION

Corresponding Author

*E-mail: jaesook@skku.edu.

Letter

Organic Letters

ORCID

Jaesook Yun: 0000-0003-4380-7878

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENTS

This research was supported by National Research Foundation of Korea (NRF) grants (Nos. NRF-2016R1A2B4011719 and NRF-2016R1A4A1011451), funded by the Korean government (MEST). D.L. thanks the China Scholarship Council (No. 201508260066).

REFERENCES

(1) (a) Pérard-Viret, J.; Quteishat, L.; Alsalim, R.; Royer, J.; Dumas, F. In *The Alkaloids;* Knölker, H.-J., Ed.; Academic Press: New York, 2017, Vol. 78, pp 205–352. (b) Yamamura, Y.; Nakamura, S.; Itoh, S.; Hirano, T.; Onogawa, T.; Yamashita, T.; Yamada, Y.; Tsujimae, K.; Aoyama, M.; Kotosai, K.; Ogawa, H.; Yamashita, H.; Kondo, K.; Tominaga, M.; Tsujimoto, G.; Mori, T. *J. Pharmacol. Exp. Ther.* **1998**, 287, 860. (c) Matsuhisa, A.; Kikuchi, K.; Sakamoto, K.; Yatsu, T.; Tanaka, A. *Chem. Pharm. Bull.* **1999**, 47, 329. (d) Kawase, M.; Saito, S.; Motohashi, N. *Int. J. Antimicrob. Agents* **2000**, *14*, 193. (e) Palma, A.; Yépes, A. F.; Leal, S. M.; Coronado, C. A.; Escobar, P. Bioorg. Med. Chem. Lett. **2009**, *19*, 2360.

(2) (a) Wagman, A. S.; Cirz, R.; McEnroe, G.; Aggen, J.; Linsell, M. S.; Goldblum, A. A.; Lopez, S.; Gomez, M.; Miller, G.; Simons, L. J.; et al. *ChemMedChem* **2017**, *12*, 1687. (b) Laponogov, I.; Pan, X.-S.; Veselkov, D. A.; Cirz, R. T.; Wagman, A.; Moser, H. E.; Fisher, L. M.; Sanderson, M. R. *Open Biol.* **2016**, *6*, 160157.

(3) (a) Aramaki, Y.; Seto, M.; Okawa, T.; Oda, T.; Kanzaki, N.; Shiraishi, M. Chem. Pharm. Bull. 2004, 52, 254. (b) Seto, M.; Aramaki, Y.; Imoto, H.; Aikawa, K.; Oda, T.; Kanzaki, N.; Iizawa, Y.; Baba, M.; Shiraishi, M. Chem. Pharm. Bull. 2004, 52, 818. (c) Seto, M.; Aramaki, Y.; Okawa, T.; Miyamoto, N.; Aikawa, K.; Kanzaki, N.; Niwa, S.-I.; Iizawa, Y.; Baba, M.; Shiraishi, M. Chem. Pharm. Bull. 2004, 52, 577. (d) Seto, M.; Miyamoto, N.; Aikawa, K.; Aramaki, Y.; Kanzaki, N.; Iizawa, Y.; Baba, M.; Shiraishi, M. Bioorg. Med. Chem. 2005, 13, 363. (e) Seto, M.; Aikawa, K.; Miyamoto, N.; Aramaki, Y.; Kanzaki, N.; Takashima, K.; Kuze, Y.; Iizawa, Y.; Baba, M.; Shiraishi, M. J. Med. Chem. 2006, 49, 2037.

(4) Contreras-Romo, M. C.; Correa-Basurto, J.; Padilla-Martínez, I.; Martínez-Archundia, M.; Martínez-Ramos, F.; Slusarz, M. J.; López-Pérez, G.; Quintanar-Stephano, A. *Med. Chem. Res.* **2014**, *23*, 1581.

(5) (a) Dolman, S. J.; Schrock, R. R.; Hoveyda, A. H. Org. Lett. 2003, 5, 4899. (b) Martínez-Estíbalez, U.; Sotomayor, N.; Lete, E. Tetrahedron Lett. 2007, 48, 2919.

(6) (a) Alcaide, B.; Almendros, P.; Aragoncillo, C.; Redondo, M. C. J. Org. Chem. 2007, 72, 1604. (b) Yu, L.-Z.; Xu, Q.; Tang, X.-Y.; Shi, M. ACS Catal. 2016, 6, 526. (c) Yu, L.-Z.; Zhu, Z.-Z.; Hu, X.-B.; Tang, X.-Y.; Shi, M. Chem. Commun. 2016, 52, 6581. (d) Zhao, Y.; Chen, J.-R.; Xiao, W.-J. Org. Lett. 2018, 20, 224.

(7) (a) Cendón, B.; Casanova, N.; Comanescu, C.; García-Fandiño, R.; Seoane, A.; Gulías, M.; Mascareñas, J. L. Org. Lett. 2017, 19, 1674.
(b) Wu, L.; Meng, Y.; Ferguson, J.; Wang, L.; Zeng, F. J. Org. Chem. 2017, 82, 4121.

(8) He, H.; Liu, W.-B.; Dai, L.-X.; You, S.-L. Angew. Chem., Int. Ed. 2010, 49, 1496.

(9) (a) Barluenga, J.; Fañanás-Mastral, M.; Aznar, F. Chem. - Eur. J.
2008, 14, 7508. (b) Jadhav, A. M.; Pagar, V. V.; Liu, R.-S. Angew. Chem., Int. Ed. 2012, 51, 11809.

(10) (a) Hino, K.; Nagai, Y.; Uno, H. *Chem. Pharm. Bull.* **1988**, *36*, 2386. (b) Liu, Y.; Tse, Y.-L. S.; Kwong, F. Y.; Yeung, Y.-Y. *ACS Catal.* **2017**, *7*, 4435.

(11) (a) Li, C.; Li, X.; Hong, R. Org. Lett. 2009, 11, 4036. For Aucatalyzed intramolecular cyclization, see: (b) González-Gómez, Á.; Domínguez, G.; Pérez-Castells, J. Eur. J. Org. Chem. 2009, 2009, 5057.
(c) Kothandaraman, P.; Huang, C.; Susanti, D.; Rao, W.; Chan, P. W.

H. Chem. - Eur. J. 2011, 17, 10081. (d) Liu, J.; Liu, Y. Org. Lett. 2012, 14, 4742. (e) Pagar, V. V.; Liu, R.-S. Angew. Chem., Int. Ed. 2015, 54, 4923. For Pd-catalyzed intramolecular cyclization, see: (f) Denis, J. G.; Franci, G.; Altucci, L.; Aurrecoechea, J. M.; de Lera, A. R.; Álvarez, R. Org. Biomol. Chem. 2015, 13, 2800.

(12) For the generation of allycopper species from allylboronates by transmetalation, see: (a) Wada, R.; Shibuguchi, T.; Makino, S.; Oisaki, K.; Kanai, M.; Shibasaki, M. J. Am. Chem. Soc. 2006, 128, 7687. (b) Vieira, E. M.; Snapper, M. L.; Hoveyda, A. H. J. Am. Chem. Soc. 2011, 133, 3332. From allenes, see: (c) Rae, J.; Yeung, K.; McDouall, I. J. W.; Procter, D. J. Angew. Chem., Int. Ed. 2016, 55, 1102. (d) Yeung, K.; Ruscoe, R. E.; Rae, J.; Pulis, A. P.; Procter, D. J. Angew. Chem., Int. Ed. 2016, 55, 11912. (e) Liu, R. Y.; Yang, Y.; Buchwald, S. L. Angew. Chem., Int. Ed. 2016, 55, 14077. (f) Jang, H.; Romiti, F.; Torker, S.; Hoveyda, A. H. Nat. Chem. 2017, 9, 1269. From dienes, see: (g) Jiang, L.; Cao, P.; Wang, M.; Chen, B.; Wang, B.; Liao, J. Angew. Chem., Int. Ed. 2016, 55, 13854. (h) Li, X.; Meng, F.; Torker, S.; Shi, Y.; Hoveyda, A. H. Angew. Chem., Int. Ed. 2016, 55, 9997. (i) Smith, K. B.; Brown, M. K. J. Am. Chem. Soc. 2017, 139, 7721. (j) Smith, K. B.; Huang, Y.; Brown, M. K. Angew. Chem., Int. Ed. 2018, 57, 6146. (k) Jia, T.; He, Q.; Ruscoe, R. E.; Pulis, A. P.; Procter, D. J. Angew. Chem., Int. Ed. 2018, 57, 11305.

(13) (a) Li, D.; Kim, J.; Yang, J. W.; Yun, J. *Chem. - Asian J.* 2018, 13, 2365. (b) Zhang, G.; Cang, A.; Wang, Y.; Li, Y.; Xu, G.; Zhang, Q.; Xiong, T.; Zhang, Q. *Org. Lett.* 2018, 20, 1798. For racemic intramolecular cyclization, see: (c) Wang, H.-M.; Zhou, H.; Xu, Q.-S.; Liu, T.-S.; Zhuang, C.-L.; Shen, M.-H.; Xu, H.-D. *Org. Lett.* 2018, 20, 1777.

(14) For an intermolecular borylative coupling of alkenes with imines, see: Smith, J. J.; Best, D.; Lam, H. W. *Chem. Commun.* **2016**, *52*, 3770.

(15) The relative configuration of **2a** was determined by NOE analysis, see the Supporting Information for details.

(16) Either borylcupration or cyclization step might be affected by the electronic factors of the substituent. See Scheme 5 and the Supporting Information for data: Lee, J.; Radomkit, S.; Torker, S.; DelPozo, J.; Hoveyda, A. H. *Nat. Chem.* **2017**, *10*, 99.

(17) The absolute configuration of *cis*-2a is tentatively assigned.

(18) It has been reported that the (Z)- σ -allylcopper species is produced by 1,4-borylcupration or 1,4-silylcupration of pure (E)dienes, see: (a) Sardini, S. R.; Brown, M. K. J. Am. Chem. Soc. 2017, 139, 9823. (b) Liepins, V.; Bäckvall, J.-E. Eur. J. Org. Chem. 2002, 2002, 3527. The formation of (Z)- σ -allylcopper species from (Z)diene was also observed by us. See the Supporting Information for details.